Tag:
Catalent Pharma
Latest Headlines
Latest Headlines
Catalent adds fast-dissolve tech to oral dose arsenal
Adding to its store of technology weapons, Catalent Pharma can now offer fast-dissolve tablet technology to clients. It obtained the development rights to Lyopan from Pantec. The lyophilized tablets
ALSO NOTED: Rebif gets EU nod; Bayer buys Citracal;
> Merck Serono got the EU nod to market a new version of the relapsing multiple sclerosis med Rebif. The new formulation, designed to be better tolerated when injected, will launch next month;
